Dupont Capital Management Corp Cerevel Therapeutics Holdings, Inc. Transaction History

Dupont Capital Management Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$23.5 - $35.38 $84,788 - $127,651	-3,608 Closed	0 $0
Q4 2021 Jan 31, 2022	BUY	$29.21 - $44.64 $105,389 - $161,061	3,608 New	3,608 $117,000
Q2 2021 Jul 30, 2021	SELL	$12.56 - $29.69 $12 - $29	-1 Closed	0 $0
Q4 2020 Jan 28, 2021	BUY	$9.82 - $18.27 $9 - $18	1 New	1 $0

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.